Alternate Day Caloric Restriction And Glp-1 Agonists

Introduction The widespread prevalence of obesity and its adverse health effects have made sustained weight loss strategies a public health priority. While the causes of obesity are still debated, 1 it is well established that a chronic positive or negative energy balance results in weight gain or loss, respectively. Caloric restriction (CR) with optimal nutrition has the potential to reverse ...

Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly prescribed for people living with obesity and type 2 diabetes due to their efficacy in reducing appetite and body weight. However, by inducing caloric restriction and altering gastrointestinal physiology, GLP-1RAs may predispose patients to nutritional deficiencies. This review aimed to synthesise ...

Such details provide a deeper understanding and appreciation for Alternate Day Caloric Restriction And Glp-1 Agonists.

Background Glucagon-like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP-1s) are shifting the treatment landscape for obesity. However, real-world ...

Moving forward, it's essential to keep these visual contexts in mind when discussing Alternate Day Caloric Restriction And Glp-1 Agonists.

This article highlights the benefits of healthy nutrition and physical activity for type 2 diabetes management irrespective of GLP-1 receptor agonist use or associated weight loss, identifies barriers to healthy nutrition and physical activity, and provides guidance for primary care clinicians to further educate and advise their patients on ...

Glucagon-like peptide 1 receptor agonists and combination medications (hereafter collectively referred to as GLP-1s) are shifting the treatment landscape for obesity. However, real-world challenges and limited clinician and public knowledge on nutritional and lifestyle interventions can limit GLP-1 efficacy, equitable results, and cost-effectiveness.